Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Summer;17(3):1099-1104.

The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention

Mohammad Haji Aghajani  1 , Farzad Kobarfard  2 , Seyed Pouzhia Shojaei  3 , Froozan Ahmadpour  4 , Olia Safi  4 , Neda Kazemina  4 , Naeime Zarepishe  4 , Mohammad Sistanizad  3   4
Affiliations
Free PMC article

The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention

Mohammad Haji Aghajani et al. Iran J Pharm Res. 2018 Summer.
Free PMC article

Abstract

The aim of current study was evaluating the frequency of clopidogrel resistance and its impact on clinical outcome of patients in Iranian patients. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who received standard dosage of clopidogrel (Plavix®, Sanofi, France, 600 mg loading dose and 75 mg/day afterward) were recruited. Platelet aggregation was measured using light transmission aggregometer. The patients were categorized as responder (platelet aggregation less than 43%) and non-responder (platelet aggregation more than 43%). All patients were evaluated for major adverse cardio vascular events one month and 3 years after the angioplasty based on MACE criteria by phone contact. One hundred and five patients with average age of 60.30 ± 12.2 years entered the study of whom 26 (24.76%) did not respond to clopidogrel. None of patients experienced cardiac events one month after PCI. Three years after PCI, data were collected from 55 (69.62%) and 10 (38.46%) subjects in responder and non-responder groups, respectively. MACE criteria was positive in 4 patients, 3 (5.45%) in responder and 1 (10%) in non-responder group (p = 0.28). We did not find any significant differences between clopidogrel resistance and past medical history. In drug history 1 (1.26%) and 4 (15.38%) patients received omeprazole with clopidogrel in responder and none-responder group, respectively (p = 0.003). This study showed 24.76% resistance to clopidogrel in Iranian population but, we did not find any correlation between clopidogrel resistance and cardiac events in follow up maybe due to study limitations particularly missed follow-up in non-responder patients.

Keywords: Drug resistance; Light transmission aggregometer; MACE; Percutaneous coronary intervention; Platelet aggregation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of platelet aggregation in study subjects 24 h after receiving clopidogrel.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wald NJ, Luteijn JM, Morris JK, Taylor D, Oppenheimer P. Cost–benefit Analysis Of The Polypill In The Primary Prevention Of Myocardial Infarction And Stroke. Eur. J. Epidemiol. 2016:415–26. - PMC - PubMed
    1. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL, Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP. Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association. Circulation . 2011;124:967–90. - PubMed
    1. Correll M, K Johnson C, Ferrari G, Brizzio M, WC Mak A, Quackenbush J, E Shaw R, Zapolanski A, B Grau J. Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting. Genomics . 2013;101:313–7. - PMC - PubMed
    1. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, 2nd , Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 2007;5:2429–36. - PubMed
    1. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Cmaj. 2006;174:1715–22. - PMC - PubMed

LinkOut - more resources